ArticleRadiation oncology (London, England)2025
Risk of cardiovascular-related death after radiotherapy for thoracic cancer.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiotoxicity following thoracic radiotherapy remains a critical issue, and this study aimed to assess the risk of Cardiovascular-Related Death (CVRD) after thoracic radiotherapy while comparing the risk of CVRD at different cancer sites. Data on patients with thoracic cancers treated with radiotherapy between 2000 and 2020 were analyzed, and the risk of CVRD was evaluated using death rates, Fine-Gray competing risks model, standardized mortality ratio (SMR), absolute excess risk (AER), and Cox regression to develop a predictive model. Patients receiving radiotherapy for thoracic cancer had a significantly increased risk of CVRD compared with the general population (Overall AER = 28.59, SMR = 2.37, 95% CI: 2.33-2.40). The risk of CVRD after radiotherapy was significantly lower in the right chest than the left (HR = 0.84, 95% CI: 0.79-0.89) and significantly higher in the left lower lung than in the upper (HR = 1.11, 95% CI: 1.01-1.22). A predictive model for the risk of CVRD in patients with left lower lung after radiotherapy was further constructed (C-index = 0.67, 95% CI: 0.67-0.68). The findings highlight that thoracic radiotherapy significantly increases cardiovascular disease risk, with patients with left lower lung cancer exhibiting the highest CVRD risk. A robust predictive model was developed, offering valuable insights for managing and predicting CVRD risk in thoracic malignancies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.